Oncolytics Biotech (TSE:ONC) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Oncolytics Biotech has announced the completion of the initial safety phase enrollment for the GOBLET trial’s new pancreatic cancer cohort, which aims to enhance treatment options with their flagship drug pelareorep. The trial, backed by a $5 million award from the Pancreatic Cancer Action Network, seeks to evaluate the drug’s efficacy in combination with other treatments, potentially offering new hope for pancreatic cancer patients.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
